Clinical Use of Tecovirimat (Tpoxx) for Treatment of Monkeypox Under an Investigational New Drug Protocol — United States, May–August 2022
Kevin O’Laughlin(Response Biomedical (Canada)), Max Veillard, Riad Elmor, Rachel E. Avery(University of Surrey), Rachel Clinton(Computer Emergency Response Team), Farrell A. Tobolowsky, Andrew Schwenk, Monique S. Davis, Jahnae Morgan, Kim Belanger Giguere, Corinne M. Parker, Agam K. Rao, Ellery Rybak, Meryl Henry, Inger K. Damon(Emory University), Sujeith B. Lozoya, Joi Brownlee, Kevin Chatham‐Stephens(National Center for Emerging and Zoonotic Infectious Diseases), Marie Dubreus, Jessica van Loben Sels, Patricia Yu(Centers for Disease Control and Prevention), Siobhán O’Connor, Taylor Coleman, Rahsaan Overton, Kalimah Muhammad, Yon Yu(Department of Human Services), Maggie X. Cheng, Catherine Campbell(Guy's and St Thomas' NHS Foundation Trust), Sarah Ahmadi, K. Bean, Leah Beavers, Nigel Peters, Brett W. Petersen(Centers for Disease Control and Prevention)
Cited by 139
Related Papers
Human Ebola virus infection results in substantial immune activation
|Proceedings of the National Academy of Sciences|2015|313
Monkeypox Outbreak — Nine States, May 2022
|MMWR Morbidity and Mortality Weekly Report|2022|309
Monkeypox in a Traveler Returning from Nigeria — Dallas, Texas, July 2021
|MMWR Morbidity and Mortality Weekly Report|2022|277
Nonfoodborne<i>Vibrio</i>Infections: An Important Cause of Morbidity and Mortality in the United States, 1997–2006
|Clinical Infectious Diseases|2008|206